Business Wire

CA-HALIO

16.11.2023 14:01:35 CET | Business Wire | Press release

Share
HALIO, the Industry’s Leader in Smart Glass Technology, Raises $70M from Korea’s SKC to Impact the Environment and Energy Savings

HALIO, designer of the world’s fastest, most beautiful, eco-friendly, and technologically advanced electrochromic (smart) glass, and SKC Ltd., a leading company in the ESG Materials Solution industry based in South Korea, today announced that HALIO has raised up to $70M in funding from SKC to further market and develop the industry’s next generation of smart glass technology, focusing on energy savings, environmental impact, and creating beautiful facades, while enabling occupant wellness and comfort.

“This investment is expected to further expand our ESG strategy,” said SKC’s Vice President Junghwan Shin. “We strongly believe that HALIO has the most advanced smart glass technology that will significantly impact global energy savings and our environment,” emphasized Shin.

In conjunction with the funding announcement, HALIO also announced the appointment of Doug Schendt as the company's new CEO, replacing Bruce Sohn, who has served as CEO since 2020. Sohn is retiring after successfully leading the company through this latest milestone.

"I'm thrilled to take on this new role and lead HALIO into its next phase of growth," said Schendt. "Having previously led our Asia operations, I'm excited to now head HALIO globally. Bruce's vision and leadership have positioned us well, and I look forward to building on that strong foundation."

HALIO Smart Glass enables architects to design beautiful and elegant facades, supporting building owners’ pursuit of providing occupants with the most comfortable, productive, and healthy interior environments. HALIO’s Sky Camera, tint algorithms, and control automation, coupled with the industry’s fastest switching speed (within seconds), make HALIO the only smart glass solution that truly optimizes daylight control and solar heat gain management in real-time.

HALIO's smart glass technology reduces a building's operational energy use by up to 22%. It decreases peak demand by 25%, which is vital in balancing overstressed power grids (Red Car Analytics - Energy Efficiency Analysis of HALIO, Nov 2019). With countries now targeting buildings as major energy users, regulations increasingly require more efficient facades. Additionally, new incentives like the U.S. Investment Tax Credit reward owners for adding energy-saving solutions like HALIO Smart Glass.

"This new capital enables us to accelerate innovation in our smart glass technology as well as expand our reach in key markets like Asia, Europe, and the Middle East," added Sohn. "This is an incredibly exciting time for HALIO. I'm proud of what we've accomplished and am confident that with Doug as CEO, the company is in great hands to continue our mission and bring our products to customers globally."

About HALIO

HALIO Smart Glass is the world’s fastest and most advanced electrochromic (smart glass) technology, enabling maximum control of daylight while optimizing energy savings by reducing solar heat gain and minimizing glare. Powered by HALIO windows and skylights are available directly from the HALIO and third-party fabricators, including Viracon and GLASSBEL, with various glass coatings and configurations. Beautiful buildings deserve beautiful facades. Find out more what HALIO can do for your next building project at www.halioinc.com.

About SKC

For the past 40 years, SKC has focused on developing materials to create a better world, positioning today as a ‘Materials Solution Company’. SKC has recently reorganized its business portfolio, centering around rechargeable batteries, semiconductors, and eco-friendly materials. Our goal is to provide new values to customers with state-of-the-art technology and earn support and trust from both customers and society, with the vision of becoming a ‘Global Major ESG Eco-Friendly Materials Solution Company’. SKC will continue to make ceaseless challenge and innovation. Learn more: http://www.skc.co.kr/eng/main/index.do

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20231116891065/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Pelago Bioscience Acquires RG Discovery, Forming an Integrated Drug Discovery Partner Spanning Biology and Chemistry15.6.2026 09:00:00 CEST | Press release

The combination unites Pelago Bioscience’s industry-leading and proprietary cellular target engagement capabilities with RG Discovery’s deep medicinal chemistry and custom synthesis expertise - enabling customers to advance drug discovery programs across the full design-make-test-analyze-(DMTA) cycle with a single specialist partner. Pelago Bioscience, a specialist drug discovery focused contract research organization (CRO), known for its industry-leading cell-based target engagement assays, is pleased to announce the acquisition of RG Discovery, and thereby adding deep expertise in medicinal chemistry, custom synthesis, and integrated drug discovery. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260615340933/en/ Michael Dabrowski, Chief Executive Officer of Pelago Bioscience By combining Pelago Bioscience's biology-focused capabilities with RG Discovery's chemistry expertise, the enlarged platform will enable drug discover

LTM Launches BlueVerse™ for iRun to Outcreate Managed Services in the Agentic AI Era15.6.2026 08:10:00 CEST | Press release

AI-native operations model enables enterprises to move from reactive service delivery to intelligent, outcome-driven managed services LTM, the Business Creativity partner to the world’s largest enterprises, today announced the launch of BlueVerse™ for iRun, an AI-native managed services model designed to transform traditional IT operations into a resilient, intelligent, and outcome-driven operating model. As enterprise environments grow more complex—spanning hybrid cloud, SaaS, and AI-driven ecosystems—traditional managed services models are increasingly constrained by siloed teams, static processes, and effort-led scaling. BlueVerse for iRun addresses this shift by moving beyond headcount-based delivery to a platform-led approach powered by agentic AI, knowledge convergence, and process-as-code. Built on the BlueVerse ecosystem, iRun creates a unified intelligence layer that brings together enterprise data, telemetry, workflows, and operational context—enabling AI to reason across sys

Azafaros to Present at BIO International Convention 202615.6.2026 07:00:00 CEST | Press release

Azafaros, a private company building a portfolio to become a leader in lysosomal storage disorders (LSDs), focused on addressing neurological symptoms, today announced that it will present at the 2026 BIO International Convention taking place in San Diego, USA, from June 22-25. The company’s presentation is scheduled for Monday, June 22 at 4:30 PM in Theater 4. The presentation will highlight Azafaros’ progress in developing nizubaglustat, its lead investigational compound for the treatment of rare lysosomal storage disorders with neurological involvement, including GM1 and GM2 gangliosidoses (GM1/GM2) and Niemann-Pick type C disease (NPC). Nizubaglustat is currently in two Phase 3 registrational studies (NAVIGATE) treating patients with GM1/GM2 and NPC and expects to report topline data from the studies in 2028. “BIO provides an important opportunity to update our progress as we continue advancing nizubaglustat through late-stage clinical development,” said Stefano Portolano, CEO at A

Teledyne FLIR Defense Launches Black Recon™ Autonomous Micro-Drone15.6.2026 06:05:00 CEST | Press release

Autonomous launch, recovery, and recharge from military vehicles and fixed installations; Three-drone rotation provides persistent surveillance and real-time targeting data in contested environments Teledyne FLIR Defense, part of Teledyne Technologies Incorporated (NYSE: TDY), today announced at Eurosatory the market launch of Black Recon™, an autonomously launched micro-drone system that delivers continuous, untethered reconnaissance from military vehicles and fixed installations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260614388428/en/ Teledyne FLIR Defense announced at Eurosatory the market launch of Black Recon™, an autonomously launched micro-drone that delivers continuous, untethered reconnaissance from military vehicles and fixed installations. Black Recon allows crews to launch, operate, recover, and recharge up to three UAS without leaving their platform, reducing operator risk. Designed for vehicle integrati

OM Pharma to Unveil the Largest Multi-Country Real-World Evidence Study on Broncho‑Vaxom® (OM‑85) for RTI Prevention at EAACI 202614.6.2026 10:00:00 CEST | Press release

REACH study met its first primary endpoint, showing that Broncho‑Vaxom® (OM‑85) was associated with a 28-38% reduction in respiratory tract infection rates at 12 months and 29-41% reduction at 24 months, comparing post-treatment versus pre-treatment initiation.1 The reduction was observed regardless of the frequency of respiratory tract infections in the previous year (1-3, >3) and across age subgroups (1-5, 6-11, 12-17, 18-64, >64 years).1 By reflecting everyday clinical practice and capturing episodes that necessitated a visit to the doctor, these extensive data offer critical new evidence of the therapy’s long-term relevance for patients suffering from recurrent respiratory tract infections. Evaluating a vast cohort of more than 15,790 paediatric, adolescent, adult and elderly patients in China, Italy, and Belgium, REACH represents the largest and only multi-country real-world evidence study to date for Broncho-Vaxom®.1,2 The study cohort includes patients with different co-morbidit

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye